Fig. 3.

Activation of AMPK reversed the anti-EGFR antibodies resistance induced by Kras mutation. a MTS analysis of DLD1 WT (+/−) transfected with control or AMPK shRNA and treated with Cet (left) or Pan (right) at the indicated doses for 48 h. b DLD1 WT (+/−) transfected with control or AMPK shRNA were treated with 5 nM Cet or 10 nM Pan for 48 h. The apoptosis was analyzed by annexin-V staining followed by flow cytometry analysis. c Hochst 33,258 staining of DLD1 WT (+/−) cells treated as in (b). d Western blot of indicated proteins in the cells treated as in (b). e The apoptosis of DLD1 WT or Kras mutation cells treated with 5 μM metformin in combined with 5 nM Cet (left) or 10 nM Pan (right) for 48 h. f The apoptosis of DLD1 WT or Kras mutation cells treated with 1 μM AICAR in combined with 5 nM Cet (left) or 10 nM Pan (right) for 48 h. Each experiment was repeated for 3 times. *, p < 0.05; **, p < 0.01